The study shows that vaccines have a much lower risk of blood clots than COVID-19
London – A study by researchers at Oxford University in England suggests that those who catch the blood are much more likely to have dangerous, less common blood clots in the brainthan those who received either the AstraZeneca vaccine or those made in the US by Pfizer and Moderna.
Another finding of research denied by Pfizer and labeled “confusing” by the leading infectious disease expert in the United States was that the number of people who develop clots after receiving the vaccines made by the American companies , appears to be very similar to the number the rare disease gets after a shot of the AstraZeneca drug developed in partnership with the Oxford Vaccines Institute.
The main finding of the study, which was published as a “pre-print” study on Thursday and has yet to be reviewed by other scientists, was that the risk of getting a blood clot in the brain in people who contract COVID is about 95 times higher. 19 than in the general population.
This is another serious health threat associated with the disease, and one that scientists hoped would build confidence in all of the major vaccines currently available in the western world, as their research suggests the drugs have a significantly lower risk of clotting than the disease they have. It has been shown to be fighting back.
“This is further evidence that the vaccine is dramatically helping people through the ravages of COVID-19,” said CBS News medical advisor Dr. David Agus, on the study for “CBS This Morning”.
The analysis of real-world data, compiled by the global health research network TriNetX and European agencies, included information on hundreds of thousands of people who have either caught or received COVID-19, Pfizer or Moderna recordings. Most of the data on the mRNA-type vaccines, which are American drugs, came from the US, while most of the data on the AstraZeneca vaccines came from the European mass vaccination programs.
The data showed that about 4 in 1 million people who received the American-made vaccines had cerebral vein thrombosis (CVT), or blood clots in the brain. With the AstraZeneca vaccine, which works differently and is similar to itThe study found an incidence rate of about 5 per 1 million.
This equates to a 10 times higher risk of CVT for people contracting the coronavirus than for those receiving the Pfizer or Moderna vaccines, and an 8 times higher risk for people receiving the AstraZeneca shot has been.
In a statement released Thursday after the Oxford data was released, Pfizer said its own “comprehensive assessment of ongoing aggregate safety data … does not suggest that arterial or venous thromboembolic events, with or without thrombocytopenia, pose a risk.” with the use of our COVID-19 vaccine. “
Pfizer noted that a CDC review of the data found slightly more cases of CVT in people given the Johnson & Johnson vaccine in the United States. “However, no similar results were seen with the approved Pfizer BioNTech vaccine.”
Even the authors of the Oxford Pre-Print Study admitted that “all comparisons must be interpreted with caution as data is still generated”.
Dr. Anthony Fauci, director of the US National Institute of Allergies and Infectious Diseases and best medical advisor to President Biden, called the study’s conclusions on comparing the different types of vaccines “confusing” and said how they were made comparisons couldn’t be made realistic become.
“Suggest that complication [CVT] Following one vaccine is similar to the other … it’s impossible how this study was designed and conducted to make that decision, “Fauci told US lawmakers on Thursday.
Citing what he called “many, many … procedural loopholes,” in the way the study was conducted, Fauci said he believes that peer review “removes that confusion, and it does it will be clear that it cannot, in the way that is planned, make a statement about the adverse events after vaccination with the mRNA as compared to everything else. “
However, Fauci did not deny the study’s core finding that “the incidence of this undesirable cerebral vein thrombosis situation increases very significantly” in people who get COVID-19.
The Oxford researchers noted that it was still unclear whether “COVID-19 and vaccines lead to CVT by the same or different mechanisms,” and said that this would be the subject of their ongoing research.
“There are concerns about possible links between vaccines and CVT, leading governments and regulators to restrict the use of certain vaccines,” noted Paul Harrison, professor of psychiatry and head of the Oxford Translational Neurobiology Group, when the UK study data was released Thursday . “We reached two important conclusions. First, COVID-19 significantly increases the risk of CVT and adds to the list of blood clotting problems caused by this infection. Second, the risk of COVID-19 is even higher than current vaccines for those under 30 years of age; this should be taken into account when considering the balance between risks and benefits for vaccination. “
The Oxford research found that around 39 out of 1 million people who contract COVID-19 are likely to have clots in their brains. The scientists stressed that the purpose of their research is not to compare vaccines, but to collect solid data on the risks of all vaccines compared to the risks associated with catching COVID-19.
“The signals that COVID-19 is linked to CVT and portal vein thrombosis – a coagulation disorder of the liver – are clear and should be noted,” said Dr. Maxime Taquet, another researcher in the Translational Neurobiology group.